Clinical Review: Treatment of Vitreoretinal Lymphoma

REFERENCES

• Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36:564–578.
   PubMed Web of Science ®Google Scholar
• Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histo-pathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242:901–913.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Chan CC, Wilson WH, et al. International Central Nervous System and Ocular Lymphoma Workshop: Recommendations for the Future. Ocul Immunol Inflamm. 2006;14:139–144.
   PubMed Web of Science ®Google Scholar
• Grimm SA, McCannel CA, Omuro AMO, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71:355–1360.
   Google Scholar
• Peterson K, Gordon KB, Heinemann MH, et al. The clinical spectrum of ocular lymphoma. Cancer. 1993;72:843–849.
   PubMed Web of Science ®Google Scholar
• Cassoux N, Merle-Beral H, Leblond V, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243–250.
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68:835–853.
   PubMed Web of Science ®Google Scholar
• Choi JY, Kafkala C, Foster CS. Primary intraocular lymphoma: a review. Semin Ophthalmol. 2006;21:125–133.
   PubMedGoogle Scholar
• Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901–903.
   PubMed Web of Science ®Google Scholar
• Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol. 2007;18:1851–1855.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol. 2002;13:531–538.
   PubMed Web of Science ®Google Scholar
• Cooper EL, Riker JL. Malignant lymphoma of the uveal tract. Am J Ophthalmol. 1951;34:1153–1158.
   PubMed Web of Science ®Google Scholar
• Vogel MH, Font RL, Zimmerman LE, et al. Reticulum cell sarcoma of the retina and uvea. Report of six cases and review of the literature. Am J Ophthalmol. 1968;66:205–215.
   PubMedGoogle Scholar
• Margolis L, Fraser R, Lichter A, et al. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer. 1980;45:688–692.
   PubMed Web of Science ®Google Scholar
• Char DH, Margolis L, Newman AB. Ocular reticulum cell sarcoma. Am J Ophthalmol. 1981;91:480–483.
   PubMed Web of Science ®Google Scholar
• Char DH, Ljung BM, Deschênes J, et al. Intraocular lymphoma: immunological and cytological analysis. Br J Ophthalmol. 1988;72:905–911.
   PubMed Web of Science ®Google Scholar
• Char DH, Ljung BM, Miller T, et al. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology. 1988;95:625–630.
   PubMed Web of Science ®Google Scholar
• Siegel MJ, Dalton J, Friedman AH, et al. Ten-year experience with primary ocular ‘reticulum cell sarcoma’ (large cell non-Hodgkin’s lymphoma). Br J Ophthalmol. 1989;73:342–246.
   PubMed Web of Science ®Google Scholar
• Hoffman PM, McKelvie P, Hall AJ, et al. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye. 2003;17:513–521.
   PubMed Web of Science ®Google Scholar
• Hormigo A, Albreg L, Heinemann MH, et al. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Hematol.2004;126:202–208.
   PubMed Web of Science ®Google Scholar
• Isobe K, Ejima Y, Tokumaru S, et al. Treatment of primary intraocular lymphoma with radiation therapy: A multi-institutional survey in Japan. Leuk Lymphoma. 2006;47:1800–1805.
   PubMed Web of Science ®Google Scholar
• Berenbom A, Davila RM, Lin HS, et al. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye. 2007;1198–1201.
   Google Scholar
• Soussain C, Merle-Beral H, Reux I, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma. 1996;23:339–345.
   PubMed Web of Science ®Google Scholar
• Sullivan SF, Dallow RL. Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential. Ann Ophthalmol. 1977;9:401–406.
   PubMed Web of Science ®Google Scholar
• Baumann MA, Ritch PS, Harde KR, et al. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer. 1986;57:1273–1275.
   PubMed Web of Science ®Google Scholar
• Strauchen JA, Dalton J, Friedman AH. Chemotherapy in the management of intraocular lymphoma. Cancer. 1989;63:1918–1921.
   PubMed Web of Science ®Google Scholar
• Valluri S, Moorthy RS, Khan A, et al. Combination treatment of intraocular lymphoma. Retina. 1995;15:125–129.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Can Res. 2003;9:711–715.
   PubMed Web of Science ®Google Scholar
• Henson JW, Yang J, Batchelor T. Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol. 1999;17:1329.
   Google Scholar
• Gudauskas G, Ostry A, Rootman J. Concentrations of tritiated methotrexate in ocular compartments, serum and urine after subconjunctival and intravenous injection. Can J Ophthalmol. 1980;15:179–182.
   Google Scholar
• Eljarrat-Binstock E, Domb AJ, Orucov F, et al. Metho-trexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res. 2007;32:639–646.
   PubMed Web of Science ®Google Scholar
• Mason JO, Fischer DH. Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmology. 2003;110:1241–1244.
   PubMed Web of Science ®Google Scholar
• de Smet MD, Stark-Vancs V, Kohler DR, et al. Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol. 1996;121:442–444.
   Google Scholar
• Kim SK, Chan CC, Wallace DJ. Management of primary intraocular lymphoma. Curr Oncol Rep. 2005;7:74–79.
   PubMedGoogle Scholar
• Jahnke K, Thiel F, Bechrakis NE, et al. Ifosfamide or trofosfamide in patients with intraocular lymphoma. J Neurooncol. 2009;93:213–217.
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16:3000–3006.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008;26:2512–2516.
   PubMed Web of Science ®Google Scholar
• Ericson L, Karlberg B, Rosengren BHO. Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol. 1964;42:721–726.
   PubMed Web of Science ®Google Scholar
• Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115:1152–1156.
   PubMed Web of Science ®Google Scholar
• de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1999;83:448–451.
   Google Scholar
• de Smet MD. Management of non-Hodgkin’s intraocular lymphoma with intravitreal methotrexate. Bull Soc Belge Ophthalmol. 2001;279:91–95.
   Google Scholar
• Velez G, Boldt HC, Whitcup SM, et al. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers. 2002;33:329–33.
   Google Scholar
• Velez G, Yuan P, Sung BC, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119:1518–1524.
   Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709–1716.
   PubMed Web of Science ®Google Scholar
• Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: Ten years of experience. Br J Ophthalmol. 2008; 92:383–388.
   PubMed Web of Science ®Google Scholar
• Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009;27:3503–3509.
   PubMed Web of Science ®Google Scholar
• Vicuna-Kojchen J, Frenkel S, Siegal T, et al. Maculo-pathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption (BBBD). Br J Ophthalmol. 2008;92:231–235.
   Google Scholar
• Sou R, Ohguro N, Maeda T, et al. Treatment of primary intraocular lymphoma with intravitreal methotrexate. Jpn J Ophthalmol. 2008;52:167–174.
   PubMed Web of Science ®Google Scholar
• Sen HN, Chan CC. Intravitreal methotrexate resistance in a patient with primary intaocular lymphoma. Ocul Immunol Inflamm. 2008;16:29–33.
   PubMed Web of Science ®Google Scholar
• Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82:760–766.
   PubMed Web of Science ®Google Scholar
• Pulido JS, Bakri SJ, Valyi-Nagy T, et al. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina. 2007;1071–1073.
   Google Scholar
• Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab. Eye. 2007;21:1524–1527.
   PubMed Web of Science ®Google Scholar
• Mineo JF, Scheffer A, Karkoutly C, et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci. 2008;49:4738–4745.
   PubMed Web of Science ®Google Scholar
• Itty S, Olson JH, O’Connell DJ, et al. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal and intrathecal chemotherapy and/or radiotherapy. Retina. 2009;29:415–416.
   Google Scholar
• Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol. 2008;126:1002–1003.
   Google Scholar
• Gregory MS, Koh S, Huang E, et al. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Invest Ophthalmol Vis Sci. 2005;46:2495–2502.
   Google Scholar
• Li Z, Mahesh SP, Shen DF, et al. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res. 2006;66:10586–10593.
   PubMed Web of Science ®Google Scholar
• Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol. 2004;248:503–518.
   PubMedGoogle Scholar
• Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
   PubMed Web of Science ®Google Scholar